BSX vs LLY: fair value comparison
Boston Scientific Corporation and Eli Lilly and Company · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, BSX currently sits closer to the top of our discount ranking. BSX carries the stronger quality grade.
| BSX | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $47.80 | $1,149.36 |
| 12-month range | $46.73–$101.01 | $862.86–$1,160.00 |
| Sector rank | #9 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | A | D |
| Momentum grade | B | — |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: BSX fair value analysis · LLY fair value analysis